logo-loader
viewCuris Inc.

Curis climbs as biotech cites flexibility after royalty revenue deal with Oberland Capital

The company has agreed to sell for as much as $135.7 million the rights to part of the royalty revenue from a treatment approved for patients with advanced basal cell carcinoma

Building blocks symbolizing medicine
Highlights from 2018 include the start of a study of diffuse large B-cell lymphoma

Curis Inc (NASDAQ:CRIS) rallied Wednesday a day after saying in its statement of 2018 results that the deal to sell part of its royalty revenue to Oberland Capital Management LLC gives it the flexibility needed to focus on clinical work.

The biotech has agreed to sell for as much as $135.7 million the rights to part of the royalty revenue from a treatment approved for patients with advanced basal cell carcinoma. 

Shares of Curis were up 5% to $2.11 in Wednesday's pre-market Nasdaq trading.

READ: Biotech company Curis rallies on deal worth up to $135.7M to sell part of carcinoma royalty revenue

"With our recently announced agreement with Oberland Capital, we secured the financial flexibility needed to ensure we can continue to move forward aggressively in our clinical execution,” Curis President and CEO James Dentzer said in a statement.

Highlights of 2018 included the initiation of a study of a combination of fimepinostat and venetoclax in the treatment of diffuse large B-cell lymphoma. The company is also working with Aurigene Discovery Technologies Ltd to develop first-in-class therapeutics in immuno-oncology and precision oncology.

As of December 31, cash, cash equivalents, marketable securities and investments for Lexington, Massachusetts-based Curis totaled $24.3 million. The sale of a portion of royalties for the Erivedge treatment to Oberland will provide net proceeds of about $30 million before closing costs and transaction fees, the company said.

For 2018, Curis reported a net loss of $32.6 million, or $0.98 per share, compared with a net loss of $53.3 million, or $1.79 per share, a year earlier.

–Updates share prices–

Contact Dennis Fitzgerald at [email protected]


 

Quick facts: Curis Inc.

Price: 2.14 USD

NASDAQ:CRIS
Market: NASDAQ
Market Cap: $71.05 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fireweed Zinc reveals 'best ever' hole drilled at Macmillan...

  Fireweed Zinc Ltd (CVE:FWZ) CEO Brandon Macdonald tells Proactive the zinc explorer has posted encouraging drill results from the first hole this year at the Boundary Zone in Yukon, an area that could boost the Macmillan Pass project's resources and economics. Macdonald says the...

1 day, 4 hours ago

2 min read